Schempp Ashley, Lee Jill, Kearney Susan, Mulrooney Daniel A, Smith Angela R
Departments of *Pediatrics, Division of Hematology/Oncology §Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota †Children's Hospitals and Clinics of Minnesota, Minneapolis, MN ‡Division of Cancer Survivorship, St Jude Children's Research Hospital, Memphis, TN.
J Pediatr Hematol Oncol. 2016 Jan;38(1):27-31. doi: 10.1097/MPH.0000000000000444.
Iron overload is a significant cause of morbidity and mortality for patients who require frequent transfusions. We completed a prospective, cross-sectional study to evaluate the prevalence of iron overload in previously transfused childhood cancer survivors. Survivors recruited from the University of Minnesota Long-Term Follow-Up Clinic were stratified into 3 groups: oncology patients not treated with hematopoietic stem cell transplantation (HSCT) (n=27), patients treated with allogeneic HSCT (n=27), and patients treated with autologous HSCT (n=9). Serum ferritin was collected and hepatic magnetic resonance imaging (FerriScan) was obtained for those with iron overload (defined as ferritin ≥1000 ng/mL). The prevalence of iron overload in subjects with a history of allogeneic HSCT was 25.9% (95% CI, 9.4%-42.5%) compared with only 3.7% (95% CI, 0%-10.8%) in subjects treated without HSCT and 0% in subjects treated with autologous HSCT. No association was found between serum ferritin levels and the presence of cardiac, liver, or endocrine dysfunction. The prevalence of iron overload in subjects who received no HSCT or autologous HSCT is low in our study. A higher prevalence was found in patients receiving allogeneic HSCT, reiterating the importance of screening these patients for iron overload in accordance with the current Children's Oncology Group Long Term Follow-Up Guidelines.
铁过载是需要频繁输血患者发病和死亡的重要原因。我们完成了一项前瞻性横断面研究,以评估既往接受输血的儿童癌症幸存者中铁过载的患病率。从明尼苏达大学长期随访诊所招募的幸存者被分为3组:未接受造血干细胞移植(HSCT)治疗的肿瘤患者(n = 27)、接受异基因HSCT治疗的患者(n = 27)和接受自体HSCT治疗的患者(n = 9)。收集血清铁蛋白,并对铁过载患者(定义为铁蛋白≥1000 ng/mL)进行肝脏磁共振成像(FerriScan)检查。有异基因HSCT病史的受试者中铁过载的患病率为25.9%(95%CI,9.4%-42.5%),而未接受HSCT治疗的受试者中仅为3.7%(95%CI,0%-10.8%),接受自体HSCT治疗的受试者中为0%。未发现血清铁蛋白水平与心脏、肝脏或内分泌功能障碍之间存在关联。在我们的研究中,未接受HSCT或自体HSCT的受试者中铁过载的患病率较低。在接受异基因HSCT的患者中发现了更高的患病率,这再次强调了根据当前儿童肿瘤学组长期随访指南对这些患者进行铁过载筛查的重要性。